– Hugel to introduce beauty toxin in the U.S. first half of the year. – Expansion plans include 80+ countries for toxins and 70+ for fillers by 2028. – Classys targets U.S. and European markets, striving for $1 billion sales by 2030. – J.P. Morgan Healthcare Conference serves as a key platform for industry leaders.
Key Highlights of JPMHC 2025 Announcements
– Hugel to launch beauty toxin in the U.S. during the first half of the year.
– Plans to expand toxin presence to over 80 countries, and HA fillers to 70 countries by 2028.
– Classys announces U.S. entry and plans for Europe with Shurink Universe and Volnewmer.
– Aiming for $1 billion in sales and over 50% profit margin by 2030.
Hugel’s Ambitious Growth Strategy
At the J.P. Morgan Healthcare Conference 2025 held in San Francisco, Eva Hwang, Chief Financial Officer of Hugel, presented the company’s plans for global expansion. The objective is to broaden their reach to over 80 countries for toxins and 70 countries for hyaluronic acid fillers by 2028. They plan to achieve a 10% market share in the U.S. and 20-25% market share in Europe and China by 2027.
Classys Sets Sights on Major Markets
Classys outlined its strategy for entering the U.S. and obtaining European Medical Device Regulation approval. CEO Baek Seung-han emphasized the importance of targeting major markets aggressively, anticipating significant sales growth following last year’s U.S. launch of Volnewmer. Their certification efforts for Shurink Universe and Volnewmer in Europe are vital for compliance with safety standards.
Innovation and Global Recognition
Hugel is recognized as a leading South Korean biopharmaceutical firm specializing in botulinum toxins and HA fillers. Hwang stated, “We are ranked third globally and first in Asia in the field of toxins and fillers,” underscoring their rapid growth. Classys aims to ensure that their innovative skin treatments comply with key regulatory frameworks while striving for ambitious sales goals.
Significance of the J.P. Morgan Conference
The J.P. Morgan Healthcare Conference is an esteemed annual event that attracts industry leaders, innovators, and investment pioneers. This platform allows companies to showcase their latest advancements and strategic outlooks to a global audience, driving interest and potential collaboration within the healthcare sector. The event is important for establishing significant business contacts and partnerships.
Conclusion
The announcements made by Hugel and Classys at the J.P. Morgan Healthcare Conference demonstrate their commitment to global growth and innovation in the aesthetic medicine industry. Both companies are targeting significant sales goals and expanding their market presence, reinforcing the potential of K-Beauty on the international stage.
Hugel and Classys are strategically positioning themselves for significant global expansion in the aesthetic medicine market following their presentations at JPMHC 2025. Hugel aims for extensive market share in toxins and fillers, while Classys targets aggressive entry in the U.S. and Europe. Their ambitions to achieve substantial sales growth through innovative products underscore the growing influence of K-Beauty worldwide.
Original Source: www.businesskorea.co.kr
Leave a Reply